We identified women diagnosed with stage IV ER + breast cancer who received immunohistochemistry or fluorescence in situ hybridization (FISH) testing and did not receive a HER2 targeted agent (trastuzumab or lapatinib) and compared them to a matched comparison cohort of women without cancer. The gene discussed is ERBB2; the disease is breast carcinoma.